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D-amino acid substitutions at glycine postion 6 in 
GnRH-I decapeptide can possess super-agonist activity 
and enhanced in vivo pharmacokinetics. Agonists elicit 
growth-inhibition in tumorigenic cells expressing the 
GnRH receptor above threshold levels. However, new 
agonists with modified properties are required to im-
prove the anti-proliferative range. Effects of residue 
substitutions and methylations on tumourigenic 
HEK293[SCL60] and WPE-1-NB26-3 prostate cells ex-
pressing the rat GnRH receptor were compared. Pep-
tides were ranked according to receptor binding affin-
ity, induction of inositol phosphate production and cell 
growth-inhibition. Analogues possessing D-Trp6 
(including triptorelin), D-Leu6 (including leuprolide), 
D-Ala6, D-Lys6, or D-Arg6 exhibited agonist and anti-
proliferative activity. Residues His5 or His5,Trp7,Tyr8, 
corresponding to residues found in GnRH-II, were tol-
erated, with retention of sub-nanomolar/low nanomo-
lar binding affinities and EC50s for receptor activation 
and IC50s for cell growth-inhibition. His
5D-Arg6-
GnRH-I exhibited reduced binding affinity and po-
tency, effective in the mid-nanomolar range. However, 
all GnRH-II-like analogues were less potent than trip-
torelin. By comparison, three methylated-Trp6 triptore-
lin variants showed differential binding, receptor acti-
vation and anti-proliferation potency. Significantly, 5-
Methyl-DL-Trp6-Triptorelin was equipotent to triptore-
lin. Subsequent studies should determine whether 
pharmacologically enhanced derivatives of triptorelin 
can be developed by further alkylations, without sub-
stitutions or cleavable cytotoxic adducts, to improve 
the extent of growth-inhibition of tumour cells ex-
pressing the GnRH receptor. 
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Introduction 
 
Gonadotropin releasing hormone (GnRH) agonists can 
elicit cancer cell growth inhibition via activation of the 
GnRH receptor (Franklin et al. 2003). Cell growth-
inhibition usually occurs provided the receptor expres-
sion levels exceed a  certain threshold at the cell sur-
face (Franklin et al. 2003; Morgan et al. 2008 and 
2011) but the extent of growth inhibition may be con-
founded by other factors including the particular or-
ganization or mutation of the intracellular signaling 
pathways (Morgan et al. 2011). Consequently, there is 
a need to develop new GnRH agonists that are able to 
improve experimental tumour eradication and to im-
pact upon cells expressing sub-threshold levels of the 
receptor; or to affect certain cell types currently resis-
tant to the anti-proliferative effects of GnRH receptor 
activation. 
 Different approaches to the development of 
GnRH agonists have been used in the past. Histori-
cally, structure-function studies using synthetic peptide 
analogues of GnRH (Karten & Rivier 1986) led to the 
identification of super-agonists containing D-amino 
acid substitutions (Coy et al. 1976). A D-amino acid 
residue at position 6, replacing glycine in native GnRH
-I (pyroGlu1,His2,Trp3,Ser4,Tyr5, Gly6,Leu7,Arg8, 
Pro9,Gly10-NH2) increases receptor binding affinity 
and lowers the dose required to reach half-maximal 
receptor activation (Excitatory Concentration, EC50) 
(Clayton & Catt 1980). The D-amino acid also in-
creases the resistance of synthetic peptides to enzy-
matic degradation by peptidases and slows clearance in 
vivo, contributing to an increased pharmacokinetic half
-life (Barron et al. 1982, Ezan et al. 1986, Redding & 
Schally 1981). A modified D-amino acid residue, con-
taining a benzene- or a di-cyclic aromatic (‘naphthyl’) 
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moiety can be incorporated at position 6, with the 
bulkiest side-chain reported being iso-butyl-[6-(3-(2-
naphthyl)-D-alanine)]-GnRH-I. This analogue was 
estimated to be slightly more potent than the D-Trp6-
GnRH-I super-agonist, triptorelin (Ho et al. 1984, 
Nestor et al. 1982 and 1984) in bioassays available at 
that time (Clayton & Catt 1980, Loumaye et al. 1982). 
Subsequently, an extended side-chain at position 6 was 
used to introduce cytotoxic GnRH conjugates such as 
D-Lys6-doxorubicin (Janáky et al. 1992) and D-Lys6-
curcumin (Aggarwal et al. 2011). However, a draw-
back associated with cytotoxic GnRH conjugates is 
their cleavage by serum enzymes prior to GnRH recep-
tor-mediated cell targeting (Nagy et al. 2000). 
 An alternative drug development strategy 
would be to seek to improve the anti-proliferative effi-
ciency by developing new GnRH receptor agonists 
without the addition of cleavable cytotoxic adducts.  
Several studies have investigated how GnRH-II  
(pyroGlu1,His2,Trp3,Ser4, Hisr5, Gly6,Trp7,Tyr8, 
Pro9,Gly10-NH2)  interacts with the type I GnRH recep-
tor (Lu et al. 2005, Millar et al. 2008, Pfleger et al. 
2002 and 2008) and suggested that GnRH-II-like 
ligands may elicit cancer cell growth inhibition more 
potently than GnRH-I analogues (Lopez de Maturana 
et al. 2008). 
 In this study, we compared the properties of 
nine GnRH analogues possessing substitution of spe-
cific residues or side-chain methylation. Screening was 
performed using two human cell lines which stably 
express high levels of the rat GnRH receptor and 
which are reproducibly growth inhibited following 
receptor activation (Morgan et al. 2008 and 2011). 
 Three analogues possessed a D-amino acid at 
position 6 (either D-Trp6, -Lys6 or -Arg6) and a His 
residue at position 5. A further three analogues pos-
sessed an additional dual substitution at positions 7 
and 8, thus incorporating His5,Trp7,Tyr8 to generate 
GnRH-II-like peptides. Finally, three methylated -DL-
Trp6 GnRH-I peptides, modified by alkyl moiety addi-
tion to the tryptophan side-chain benzene ring posi-
tions 4, 5 or 6, were compared to the super-agonist 
triptorelin since previous studies of side-chain alkyla-
tion have only addressed position Trp3 but not the criti-
cally important position 6 (Yabe et al. 1979, Deghen-
ghi, 1997). 
 Interestingly, the GnRH-II residue substitution 
analogues were less potent than triptorelin whilst one 
of the methylated triptorelin analogues exhibited high 
potency, indicating scope for the generation of new 
triptorelin-based drugs which may possess improved 
pharmacological or pharmaco-dynamic properties for 
tumour growth inhibition. 
 
Materials and Methods 
 
Reagents 
HPLC purified synthetic peptides were purchased from 
Sigma, UK or were custom synthesized by EZ Biolabs, 
USA or Eurogentech, Germany. GnRH analogues 
were selected to enable examination of primary se-
quence differences between GnRH-I and GnRH-II. 
Methylated triptorelin isoforms were synthesised using 
readily available methylated-DL-tryptophan isomers. 
 
Cell culture 
HEK293[SCL60] cells were maintained in DMEM with 
10% fetal bovine serum containing G418. All assays 
using these cells required plates coated with matrigel. 
WPE-1-NB26-3 cells were grown in keratinocyte me-
dium supplemented with bovine pituitary extract and 
recombinant human epidermal growth factor 
(Invitrogen kit, UK). Human prostate cancer cell lines 
PC3, LNCaP and DU145 were grown in DMEM with 
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Cell Type HEK293[SCL60] WPE-1-NB26-3 
  Binding IC50, (nM) 
Inositol phosphate 
EC50, (nM) 
Binding IC50, (nM) 
Inositol phosphate 
EC50, (nM) 
Peptide  
D-Trp6 GnRH 0.5 + 0.2 0.14 + 0.01 0.9 + 0.3  0.2 + 0.03 
His5 D-Trp6 GnRH 0.8 + 0.5  0.6 + 0.2 0.3 + 0.1  0.4 + 0.1  
His5 D-Trp6Trp7Tyr8 GnRH 3.4 + 0.5  5.9 + 0.9 2.6 + 0.3  3.9 + 0.5  
His5 D-Lys6 GnRH 3.0 + 0.5  12.5 + 1.7 5.1 + 0.3  6.2 + 0.2  
His5 D-Lys6Trp7Tyr8 GnRH 0.8 + 0.2 1.7 + 0.06 0.7 + 0.2 0.8 + 0.2 
His5 D-Arg6 GnRH 22.3 + 2.3  45.0 + 6.9  27.5 + 4. 9 21.2 + 6.9  
His5 D-Arg6Trp7Tyr8 GnRH 0.5 + 0.1 1.6 + 0.2  0.9 + 0.03 0.9 + 0.2  
Table 1. Receptor binding and activation properties of GnRH analogues. 
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Figure 1. A-D. Receptor binding assays for D-6 GnRH analogues. Displacement of 125I-His5D-Tyr6 GnRH-I bound to the sur-
face of cells grown in multi-well plastic culture dishes by co-incubation with different concentrations of unlabelled GnRH ana-
logue enabled generation of curves and estimation of relative binding affinities. Examples of binding of four GnRH ligands to 
two cell lines expressing rat GnRH receptor are presented. Binding was determined in triplicate and on separate occasions for 
each data-point. E-F. Bar charts for binding IC50 values. Individual IC50 calculations were performed using the Prism software 
(Graphpad, USA), assuming a single binding site. The dashed line distinguishes sub-nanomolar values from nanomolar values. 
Error bars indicate mean + SEM, p values derived using T-test. 
10% fetal bovine serum. 
 
Whole cell binding assay 
Cells were plated in 12-well or 24-well plates for the 
125I-GnRH binding assay, using 125I-labeled His5D-
Tyr6GnRH-I as a tracer (Flanagan et al. 1998). The 
method has been described previously (Morgan et al. 
2008 and 2011). Peptide dilutions were prepared in 
HEPES-DMEM containing 0.1% BSA. Specific bind-
ing was determined in triplicate by counting gamma-
ray radiation following washing and lysis of cell 
monolayers. Inter-plate comparisons were made by 
counting the number of cells per well in plates pre-
pared in parallel. 
 
Inositol phosphate assay 
Cells were plated into 24-well plates for the 3H-
myoinositol assay, performed as described previously 
(Morgan et al. 2008 and 2011). Peptide dilutions were 
prepared in HEPES-DMEM containing 10 mM LiCl 
and 0.1% BSA. Receptor stimulation was performed at 
370C for 60 minutes. 
 
Cell growth assay 
Cells grown in 12-well plates were treated with GnRH 
receptor analogues and growth was analysed by sulfor-
hodamine B staining and spectrophotometric quantifi-
cation, as described previously (Morgan et al. 2008, 
2011). 
 
Statistical analysis 
Analyses of quantitative data were performed using 
online tools available at http://easycalculation.com/
statistics/standard-deviation.php and http://
www.quantitativeskills.com/sisa/ or using Microsoft 
Excel (T Test). All data were generated in triplicate on 
at least two separate occasions. Graphs were plotted 
using calculations of mean + standard error of mean 
(SEM) and analyzed by non-linear regression model-
ing using the Prism software (GraphPad, USA). T-Test 
P values < 0.05 were considered to be statistically sig-
nificant. 
 
Results 
 
All of the GnRH analogues studied exhibited specific 
binding to the rat GnRH receptor that was stably ex-
pressed in human embryonic kidney cells (HEK293
[SCL60]) or immortalized human prostate epithelial cells 
(WPE-1-NB26-3) (see Figure 1 and Table 1 for exam-
ples). Displacement of 125I-GnRH bound to the cell 
surface with different concentrations of unlabelled 
GnRH analogues enabled calculation of approximate 
binding affinities (IC50s, Table 1). 
 In HEK293[SCL60] and WPE-1-NB26-3 cells, D
-Trp6 GnRH-I exhibited the highest binding affinity 
compared to all residue substitution analogues tested. 
Replacement of Tyr5 by His5 had a modest effect on 
binding (Table 1). Replacement of Leu7Arg8 by 
Trp7Tyr8 to generate ‘D-Trp6-GnRH-II’ (His5 D-
Trp6Trp7Tyr8 GnRH) resulted in significantly poorer 
125I-GnRH tracer displacement. Differences between 
binding affinities for certain peptides were statistically 
significant (see Figure 1 and Table 1). 
 Introduction of a positively charged D-residue 
side chain at position 6 (D-Lys6 or D-Arg6) interfered 
with ligand binding in the D-6 substituted GnRH-I 
analogues but not in the D-6 substituted GnRH-II ana-
logues (compare results for His5 D-Lys6 GnRH or His5 
D-Arg6 GnRH with His5 D-Lys6Trp7Tyr8 GnRH and 
His5 D-Arg6Trp7Tyr8 GnRH in Table 1). 
 Comparison of GnRH analogues revealed sta-
tistically significant differences in the potency of ago-
nists to stimulate production of inositol phosphates. D-
Trp6 GnRH-I was the most potent agonist compared to 
the substitution variants (Figure 2 and Table 1). D-Trp6 
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Cell Type HEK293[SCL60] WPE-1-NB26-3 
  Cell growth inhibition IC50 , (nM) Cell growth inhibition IC50 , (nM) 
Peptide  
D-Trp6 GnRH 0.4 + 0.06 0.17 + 0.05 
His5 D-Trp6 GnRH 1.2 + 0.5 0.4 + 0.1 
His5 D-Trp6Trp7Tyr8 GnRH 0.5 + 0.06 2.3 + 0.9 
His5 D-Lys6 GnRH 24.8 + 17.6 3.1 + 1.8 
His5 D-Lys6Trp7Tyr8 GnRH 6.5  + 2.8 1.1 + 0.8 
His5 D-Arg6 GnRH 35.9 + 14.8 20.9 + 11.8 
His5 D-Arg6Trp7Tyr8 GnRH 7.5 +  2.3 0.9 + 0.4 
Table 2. Cell growth inhibition potencies of GnRH analogues. 
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Figure 2. Inositol phos-
phate assays. Titrations 
were performed to enable 
calculation of EC50s (A-
D). Bar chart representa-
tion of receptor activation 
EC50 values, where 
dashed lines emphasize 
the salient differences 
between GnRH analogues 
(E-F). GnRH analogues 
were screened for recep-
tor activation using stimu-
lation with a single dose 
of peptide (10 nM), ena-
bling rapid comparisons 
to be made prior to titra-
tions (G-H).  Error bars 
indicate mean + SEM, p 
values derived using T-
test. 
GnRH-I behaved as a super-agonist relative to native 
GnRH-I at the rat GnRH receptor expressed in 
HEK293[SCL60] and WPE-1-NB26-3 cells. Decreased 
relative potency in the other GnRH analogues corre-
lated with lower binding affinity. 
 Dose-response analyses of the effects of 
GnRH analogues on cell growth were performed 
(Figure 3), enabling calculation of IC50s (Table 2). The 
anti-proliferative potency of GnRH analogues paral-
leled binding affinities and EC50s (Tables 1 and 2). 
 Methyl adducts were incorporated into three 
separate locations within the benzene ring of the Trp6 
side-chain of DL-Trp6 GnRH-I. These peptides were 
synthesized as DL epimer mixtures (50:50% abun-
dance confirmed by HPLC analysis). Each mixture 
exhibited differential properties for binding, receptor 
activation, and inhibition of cell growth (Figure 4 and 
Table 3). 
 Methylation at position 5 of the benzene-ring 
of DL-Trp6 GnRH-I did not adversely affect the in vi-
tro binding, receptor activation or cell growth inhibi-
tory properties of the peptide relative to triptorelin (D-
Trp6 GnRH-I). Thus 5-methyl-DL-Trp6 GnRH retained 
high potency. Methylation at position 4 of the benzene
-ring of DL-Trp6 GnRH-I modestly reduced binding 
affinity, receptor activation and cell growth inhibitory 
potency. The IC50 values for binding, EC50 values for 
receptor activation and IC50 values for growth inhibi-
tion were statistically different relative to D-Trp6 
GnRH-I and 5-methyl-DL-Trp6 GnRH using both cell 
lines. Methylation at position 6 of the benzene-ring of 
DL-Trp6 GnRH-I dramatically reduced binding affin-
ity, receptor activation and cell growth inhibitory po-
tency. Growth of the prostate cell line was more sensi-
tive to the methyl-DL-Trp6 GnRH analogues than ob-
served for HEK293[SCL60] cells. 
 None of the GnRH analogues used in this 
study exhibited specific binding, inositol phosphate 
signalling or significant cell growth inhibition in non-
transfected HEK293, WPE-1-NB26, PC3, LNCaP or 
DU145 cell lines (data not shown). 
 
Discussion and Conclusions 
 
Using appropriate in vitro tools it has become possible 
to explore GnRH analog structure-function relation-
ships with increasing depth and application (Beckers et 
al. 1995, Coetsee et al. 2008, Flanagan et al. 1994 and 
2000, Fromme et al. 2001, Karten & Rivier 1986, Lo-
pez de Maturana et al. 2008, Lu et al. 2005 and 2007, 
Marheineke et al. 1998, Millar & King 1983, Millar et 
al. 1986, 2004 and 2008, Pfleger et al. 2002 and 2008, 
Sealfon et al. 1997, Söderhäll et al. 2005). One chal-
lenge is to use this technology to develop GnRH ago-
nists that are more effective than triptorelin in tumor 
growth inhibition, ultimately aiming to enable growth 
inhibition of cells with moderate to low levels of 
GnRH receptor or altered intracellular signalling path-
ways. 
 We found that new anti-proliferative agonists 
may be identified by screening for subtle changes in 
GnRH peptide structure which serve to probe the 
ligand binding site, such as side-chain alkylation. The 
latter may result in modified binding and receptor acti-
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Cell Type HEK293[SCL60] WPE-1-NB26-3 
  Binding IC50, (nM) 
Inositol phosphate 
EC50, (nM) 
Binding IC50, (nM) 
Inositol phosphate 
EC50, (nM) 
Peptide  
D-Trp6 GnRH 0.5 + 0.2 0.14 + 0.01 0.9 + 0.3 0.15 + 0.01 
6Me DL-Trp6 GnRH 2.3 + 0.2 1.70 + 0.4 2.7 + 0.3 1.05 + 0.05 
5Me DL-Trp6 GnRH 97.7 + 17.0 0.30 + 0.03 0.7 + 0.3 0.17 + 0.01 
4Me DL-Trp6 GnRH 0.6 + 0.07 36.6 + 5.10 138.5 + 26.0 11.90 +1.40 
Cell Type HEK293[SCL60] WPE-1-NB26-3 
 Cell growth inhibition IC50, (nM ) Cell growth inhibition IC50, (nM) 
Peptide  
D-Trp6 GnRH 0.4 + 0.06 0.17 + 0.05 
4Me DL-Trp6 GnRH 4.5 + 0.6 0.8 +  0.20 
5Me DL-Trp6 GnRH 0.5 + 0.06 0.1 +  0.01 
6Me DL-Trp6 GnRH 64.4 + 4.0 10.1 +  0.10 
Table 3. Receptor binding, activation and cell growth inhibitory properties of methylated triptorelin derivatives. 
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Figure 3.  Examples of GnRH analog dose-responses associated with cell growth-inhibition (A-D). Note that WPE-1-NB26-3 
cells grow more slowly than HEK293[SCL60] cells over four days, hence the difference in the scale bar for optical density at 540 
nm (O.D. 540 nm) between the two cell lines. Values for IC50 calculations are presented as bar graphs (E-G) and dashed lines 
emphasise differences in potencies. His5D-Arg6 GnRH exhibited the lowest ability to inhibit cell growth. Error bars indicate 
mean + SEM, p values derived using T-test. 
vation dynamics and altered pharmacodynamics. This 
approach is distinctly different to the development of 
GnRH conjugates containing cleavable toxic adducts 
(Nagy et al. 2000), such as GnRH-doxorubicin or 
GnRH-curcumin (Aggarwal et al. 2011), in which the 
adduct moiety is positioned on a linker to avoid con-
tact with the ligand-receptor binding site. 
 We compared the properties of GnRH ana-
logues containing a D-amino acid residue at position 6 
and combinations of residues found in GnRH-II to the 
effects of  methylation of residue 6 using two human 
cell lines expressing high levels of rat GnRH receptor 
(HEK293[SCL60] and WPE-1-NB26-3 cells). New in-
sights into GnRH agonist structure-function were ob-
tained. 
 Changing the D-amino acid residue at position 
6 and the flanking residues at position 5 and positions 
7 and 8 in a range of analogues did not improve bind-
ing affinity relative to triptorelin, (D-Trp6 GnRH-I) 
(Table 1). 
 The GnRH-II-like peptides His5D-
Arg6Trp7Tyr8- GnRH-I and His5D-Lys6Trp7Tyr8-
GnRH-I, possessed binding affinities similar to D-Trp6 
GnRH-I (Table 1). Interestingly, they bind better than 
His5D-Trp6Trp7Tyr8-GnRH-I, probably due to the way 
in which complex charge and steric interactions be-
tween side-chains affect peptide conformation and 
docking to the receptor. 
 Peptide-receptor binding affinity generally 
correlated with estimates of the EC50 for receptor acti-
vation, although EC50s were poorer than expected 
(when compared to binding IC50) for GnRH analogues 
possessing weaker binding (namely, His5D-
Trp6Trp7Tyr8 GnRH, His5D-Lys6 GnRH and His5D-
Arg6 GnRH, Table 1 and Figures 1 and 2). Perhaps 
analogues with poor binding affinity are unable to in-
duce the correct receptor conformation for optimal ac-
tivation. 
 We found that the GnRH receptor in the pros-
tate cells appeared to be more efficiently coupled to 
inositol phosphate production. This phenomenon may 
be due to higher receptor levels, 1.7 fold higher in 
prostate cells relative to HEK293[SCL60] (Morgan et al. 
2011). 
 Peptide binding and receptor activation rela-
tionships were consistent with analyses of cell growth 
inhibition (Table 2 and Figure 3), indicating that the 
level of GnRH receptor activation correlates with the 
extent of anti-proliferation in both of these cell types. 
 Incorporation of D-residues into GnRH-II-like 
analogues did not enhance binding, receptor activation 
or anti-proliferative properties relative to triptorelin (D
-Trp6 GnRH-I). Hence our results negate the hypothe-
sis that GnRH-II agonists may be more effective anti-
proliferative agents than GnRH-I agonists (Lopez de 
Maturana et al. 2008). Furthermore, corroborative data 
generated in the current study indicate that at least two 
cell models may be required to properly assess the anti
-proliferative properties of GnRH analogues, rather 
than examination of HEK293[SCL60] alone, as  used pre-
viously (Lopez de Maturana et al. 2008). We note that 
HEK293[SCL60] cells adhere to matrigel extracellular 
matrix more efficiently than to poly-L-lysine coated 
culture plates. This difference, coupled with the more 
accurate sulphorhodamine B growth assay rather than 
reliance on trypsin/manual cell counting, may account 
for inconsistencies between new data and previous 
studies. It is also possible that the use of GnRH ana-
logues possessing D-amino acid residues alters the half
-life of synthetic peptides in vitro and that this makes 
comparisons of anti-proliferative potency with native 
GnRH-II-like analogues more difficult to interpret. 
Further investigations into the in vitro stability of 
GnRH analogues are required in this respect. 
 Since triptorelin was the most potent agonist 
amongst the substitution ligands studied, further analy-
ses of the interaction of this peptide with the receptor 
were performed. The binding affinity of triptorelin to 
the rat GnRH receptor is sub-nanomolar, similar to 
other mammalian GnRH receptors (Beckers et al. 
1995) although some estimates place it at around 2 nM 
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Figure 4. Location of methyl-DL-Trp6 side-chain positions 
4, 5 and 6 on the benzene ring of the indole moiety in space-
filling depictions of methylated tryptophan. 
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Figure 5 (continued on the next page).  
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Figure 5 (continued from the previous page). Graphical analyses of bind-
ing, receptor activation and cell growth inhibition for methylated DL-Trp6 
GnRH analogues compared to D-Trp6 GnRH-I (A-F; previous page). Bar 
charts emphasize differences in affinity and potency for the various ana-
logues (G-M). Error bars indicate mean + SEM, p values derived using T-
test. 
(Pfleger et al. 2002 and 2008), probably due to less 
physiological experimental conditions (isolated cell 
membrane suspensions in which structural integrity of 
receptors is not biologically maintained by cellular 
homeostasis). Estimates of GnRH analogue binding 
affinity can vary according to the experimental assay 
and methodology employed. Levels of GTP and the 
status of receptor sulfhydryl moieties have been sug-
gested to influence estimation of GnRH ligand binding 
affinity (Hazum 1981). Other factors, including the 
relative abundance of G proteins and their regulator 
proteins may conceivably affect the GnRH receptor 
conformation through formation of multi-protein mac-
romolecular protein complexes involving the intracel-
lular face of the receptor. 
 A modified version of triptorelin, 5-methyl-DL
-Trp6 GnRH-I exhibited sub-nanomolar binding affin-
ity and potency, whereas 6-methyl-DL-Trp6 GnRH-I 
bound less well to the receptor and was much less po-
tent (Figure 4 and Table 3). We hypothesise that hy-
drophobic and steric constraints conferred by a methyl 
adduct on the Trp6 benzene ring affect the opportuni-
ties for hydrogen bonding between the Trp6 indole ni-
trogen atom and the receptor according to the precise 
location of the adduct. The methyl moiety in 4- and 6-
methyl-DL-Trp6 GnRH-I may cause steric clash. 
 These are significant discoveries, building on 
previous reports documenting the high potency of iso-
butyl-naphthyl-alanine at position 6 (Nestor et al. 1982 
and 1984). The possible effects of further methylations 
of Triptorelin on its pharmacological properties are 
intriguing. 
 Although methyl-DL-Trp6 GnRH-I enanti-
omeric mixtures were used in our studies (50:50 w/w, 
confirmed by HPLC-UV detector analysis), it is 
known that large L-amino acid side chains are not tol-
erated at position 6. Substitution of Gly6 with D-Ala6 
increased the potency of the GnRH analog to 350-
400% that of native GnRH-I, while a corresponding L-
Ala6 substitution resulted in a peptide with a potency 
of only 4% of native GnRH-I (Karten & Rivier 1986). 
As such, we would expect the EC50 of L-Trp
6 GnRH-I 
to have a potency of only 1% of D-Trp6 GnRH-I and a 
similar relationship is likely for methyl-L- and methyl-
D- Trp6 GnRH-I analogues, although this remains to 
be formally confirmed. 
 Likewise, the relatively bulky L-Asp6 side 
chain in lamprey GnRH-III results in less than 
0.0003% potency relative to mammalian GnRH-I at 
the human GnRH receptor (Neill 2002) and Ciona 
GnRH isoforms possessing an L-amino acid residue at 
position 6 bind poorly to mammalian GnRH receptor 
(Barran et al. 2005). Binding and receptor activation 
can be increased ten-fold by substitution with Gly or a 
D-amino acid at Ciona GnRH position 6 (Barran et al. 
2005). 
 Significantly, since 5-methyl-DL-Trp6 GnRH-I 
retained properties similar to triptorelin, further alkyla-
tions of the position 6 side chain may be valuable in 
attempts to improve the anti-proliferative capacity of 
GnRH receptor super-agonists. For example, introduc-
tion of hydrophobic moieties may significantly affect 
the in vivo pharmacodynamics of triptorelin deriva-
tives. These observations indicate that site-specific 
ligand methylation/alkylation may be a superior strat-
egy compared to whole residue substitutions or addi-
tion of cleavable cytotoxic adducts for the identifica-
tion of new potent anti-proliferative GnRH super-
agonists in future studies. Ligand and receptor struc-
ture-function studies and molecular modelling are re-
quired to investigate how the methylated triptorelin 
docks into the agonist binding site in the GnRH recep-
tor. 
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